<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 01, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02786537</url>
  </required_header>
  <id_info>
    <org_study_id>16-1234</org_study_id>
    <nct_id>NCT02786537</nct_id>
  </id_info>
  <brief_title>Study of Oral Treatments for Hepatitis C</brief_title>
  <acronym>PRIORITIZE</acronym>
  <official_title>THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will compare the effectiveness of 3 approved HCV treatment regimens to learn
      whether they work equally well under real-world conditions. Patients receiving HCV therapy
      in community and academic clinics will be offered the opportunity to consent to be randomly
      assigned to one of three regimens and then observed for outcomes. Once randomized, all
      medical care, laboratory testing, and any disease or side effect management will be assumed
      by usual care conditions, and patient-reported outcomes will be collected outside clinic in
      keeping with pragmatic design principles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consented subjects will be randomized to 1 of the following 3 HCV treatments:

      1) Harvoni® 2)Viekira Pak™ 3)Zepatier™ (The addition of Ribavirin and the length of
      treatment will be determined by the provider). Subjects will have up to 1 tablespoon of
      blood drawn for HCV resistance testing and future biorepository testing (if subject provides
      additional consent). The results of testing will determine whether a genotype 1a subject
      will be provided 12 or 16 wks of Zepatier (if randomized to Zepatier).

      Following randomization, subjects will complete patient reported outcome questionnaires via
      electronic device or telephone. Following randomization, subjects will be asked to complete
      surveys again at Wk 4 of treatment, End of Treatment, 1 and 3 year post treatment. Subjects
      standard medical care will continue. Test results and medical records throughout treatment
      and for up to 3 years post treatment will be collected.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Patients who Achieve Undetectable Hepatitis C Virus (HCV) RNA 12 Weeks after completing HCV treatment</measure>
    <time_frame>Post Treatment Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 will be defined as hepatitis C virus (HCV) RNA undetectable at 12 week follow-up visit (12 -24 weeks after HCV treatment discontinuation as dictated by standard of care at each individual site)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients who report missing pills (doses) (Voils' Medication Adherence Survey)</measure>
    <time_frame>12-16 weeks of HCV treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Treatment Adherence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with reduction in fibrosis 3 years (Liver Biopsy/Fibroscan) post treatment baseline</measure>
    <time_frame>3 years post treatment discontinuation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of patients with reduction in Liver Biopsy Scores/Fibroscan Scores will be assessed by comparing baseline and post-treatment liver biopsy/fibroscan scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who are HCV RNA undetectable (cured) 3 years post-treatment</measure>
    <time_frame>3 years after treatment discontinuation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients who are still undetectable (HCV RNA) 3 years post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with decrease in HCV-associated symptoms (PROMIS measures) after HCV treatment initiation</measure>
    <time_frame>1 and 3 years post treatment discontinuation</time_frame>
    <safety_issue>No</safety_issue>
    <description>6 PROMIS scores recorded at baseline and at 1 and 3 years after treatment will be used to evaluate change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who have an increase in functional status (as reported on HCV-PRO questionnaire)</measure>
    <time_frame>Baseline, 1 year, and 2 years after treatment discontinuation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of patients who have an increase in functional status (as reported on patient reported outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events that caused treatment discontinuation</measure>
    <time_frame>Treatment start date through treatment completion (up to 24 weeks)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of participants with adverse events that led to early treatment discontinuation (defined as duration less than originally prescribed treatment regimen)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3750</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>sofosbuvir/ledipasvir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will take 1 tablet sofosbuvir/ledipasvir orally once daily with or without food 12 to 24 weeks with or without RBV (per discretion of provider)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ombitasvir/paritaprevir/ritonavir and dasabuvir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two ombitasvir/paritaprevir/ritonavir once daily and dasabuvir twice daily for 12 to 24 weeks +/- RBV (provider discretion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>elbasvir/grazoprevir tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will take elbasvir/grazoprevir tablet tablet once daily with or without RBV for 12 to 16 weeks (provider discretion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sofosbuvir/ledipasvir</intervention_name>
    <description>Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)</description>
    <arm_group_label>sofosbuvir/ledipasvir</arm_group_label>
    <other_name>Harvoni® (sofosbuvir/ledipasvir)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ombitasvir/paritaprevir/ritonavir</intervention_name>
    <description>Ombitasvir/paritaprevir/ritonavir (12.5/75/50mg) for 12 to 24 weeks (treatment duration and use of ribavirin as per HCV provider)</description>
    <arm_group_label>ombitasvir/paritaprevir/ritonavir and dasabuvir</arm_group_label>
    <other_name>Viekira Pak (fixed dose combination of ombitasvir/paritaprevir/ritonavir)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>elbasvir/grazoprevir</intervention_name>
    <description>Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks with or without RBV</description>
    <arm_group_label>elbasvir/grazoprevir tablet</arm_group_label>
    <other_name>Zepatier (elbasvir/grazoprevir)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasabuvir</intervention_name>
    <description>250 mg daily for 12 to 24 weeks</description>
    <arm_group_label>ombitasvir/paritaprevir/ritonavir and dasabuvir</arm_group_label>
    <other_name>Viekira Pak</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV Genotype 1a or 1b

          -  Adult patients (age 18 years or older)

          -  Patients being prescribed HCV treatment who can begin treatment with any of the three
             HCV treatments being studied (Harvoni, Viekira Pak, or Zepatier)

        Exclusion Criteria:

          -  Inability to provide written informed consent

          -  HARVONI® is not a covered drug on benefits formulary

          -  Current or historical evidence of hepatic decompensation (variceal bleeding, hepatic
             encephalopathy, or ascites)

          -  Child Pugh (CTP) B or C Cirrhosis (documented CTP calculation is required)

          -  Pregnant or breastfeeding women
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Nelson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monika Vainorius, MD</last_name>
    <phone>919-966-2512</phone>
    <email>monika_vainorius@med.unc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lauren E Morelli, BA</last_name>
    <phone>352-273-9508</phone>
    <email>lauren.morelli@medicine.ufl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Liver Wellness Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lynn Frazier, ARNP</last_name>
      <phone>501-687-9300</phone>
      <email>LFRAZIER@ADCLR.COM</email>
    </contact>
    <investigator>
      <last_name>Alonzo Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sharon Quigley</last_name>
      <phone>858-657-5147</phone>
      <email>sjquigley@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Alexander Kuo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF/San Fran General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yu-Chi Lapid</last_name>
      <email>Yu-Chi.Lapid@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Mandana Khalili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daisy Rios</last_name>
      <phone>415-476-8063</phone>
      <email>daisy.rios@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Nora Terrault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University Digestive Diseases</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Bertuccio</last_name>
      <phone>203-785-2204</phone>
    </contact>
    <investigator>
      <last_name>Joseph Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Christian</last_name>
      <email>erica.christian@gunet.georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Coleman Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0272</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Horne, ARNP</last_name>
      <phone>352-273-9500</phone>
      <email>PATRICK.HORNE@MEDICINE.UFL.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Briana Foerman, BS</last_name>
      <phone>352-294-5152</phone>
      <email>briana.foerman@medicine.ufl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Giuseppe Morelli, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida, Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Jackman, PHD</last_name>
      <phone>904-633-0070</phone>
      <email>kelly.jackman@jax.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Miguel Malespin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami/Schiff Center for Liver Diseases</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Pavicic</last_name>
      <email>epavicic@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maria Onate-Silva</last_name>
      <email>mlourdeso@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Eugene Schiff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeff Dinsmore</last_name>
      <phone>407-409-7125</phone>
      <email>jdinsmore@oicorlando.com</email>
    </contact>
    <investigator>
      <last_name>Federico Hinestrosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Associates of Wellstar Atlanta Medical Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Brown</last_name>
      <phone>404-265-4194</phone>
      <email>dyardmon3@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Brian Pearlman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sara Lescano</last_name>
      <phone>312-694-0243</phone>
      <email>sara.lake@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Josh Levitsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martha Mendez, RN</last_name>
      <phone>317-278-4633</phone>
      <email>mwmendez@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Kwo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Hopkins University</name>
      <address>
        <city>Lutherville</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Katz, MSN,RN</last_name>
      <phone>443-287-9605</phone>
      <email>SSNEDDO2@JHMI.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Stacey Reese</last_name>
      <phone>410-955-9944</phone>
      <email>SREESE2@JHMI.EDU</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Sulkowski, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juhi Moon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane White, CCRP</last_name>
      <phone>734-763-6647</phone>
      <email>dfwhite@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Anna SF Lok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Valenzuela</last_name>
      <phone>612-624-9926</phone>
    </contact>
    <investigator>
      <last_name>Mohamed Hassan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina L Wriston, RN</last_name>
      <phone>314-977-9400</phone>
      <email>KWRISTON@SLU.EDU</email>
    </contact>
    <contact_backup>
      <last_name>Caroline Vemulapalli-Forrest</last_name>
      <email>cvemulap@slu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Adrian DiBisceglie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Ctr</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Kos, BSN</last_name>
      <phone>402-559-3652</phone>
      <email>MEKOS@UNMC.EDU</email>
    </contact>
    <investigator>
      <last_name>Mark Mailliard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southwest CARE Center</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanna Pierce</last_name>
      <email>jpierce@southwestcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Christopher Gallegos</last_name>
      <email>cgallegos@southwestcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Joel N Gallant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlene Feron-Rigodon, RN</last_name>
      <phone>646-962-2085</phone>
      <email>maf2062@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennie Chavis</last_name>
      <phone>212-305-3839</phone>
      <email>jc4380@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Verna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mountain View Medical Center</name>
      <address>
        <city>Valatie</city>
        <state>New York</state>
        <zip>12184</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ananth Ramani</last_name>
      <phone>518-943-1943</phone>
      <email>ramani489@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Anathakrishnan Ramani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Pritchett, B.A.</last_name>
      <email>tpritch@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Renee Blanchard</last_name>
      <phone>919-843-5936</phone>
      <email>renee_blanchard@med.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael W. Fried, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loranda Ross</last_name>
      <phone>919-681-2941</phone>
      <email>loranda.ross@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Muir, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liz Stambrook, BSN</last_name>
      <phone>513-584-2363</phone>
      <email>LIZ.STAMBROOK@UCHEALTH.COM</email>
    </contact>
    <contact_backup>
      <last_name>Diane Daria</last_name>
      <email>dariade@ucmail.uc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kenneth Sherman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Borges</last_name>
      <phone>215-615-3755</phone>
      <email>kelly.borges@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Rajender Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Specialist of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina McNeil</last_name>
      <phone>713-634-5110</phone>
      <email>cmcneil@texasliver.com</email>
    </contact>
    <contact_backup>
      <last_name>Wilma Regalado</last_name>
      <email>wregalado@texasliver.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph Galati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours St. Mary 's Hospital of Richmond (Liver Institute of Virginia)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Vollum, RN, CRC</last_name>
      <phone>804-977-8921</phone>
      <email>susan_vollum@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Mitchell L. Shiffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Nguyen</last_name>
      <phone>206-744-3402</phone>
      <email>hnguyen@medicine.washington.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lee McKoin</last_name>
      <phone>206-744-3402</phone>
      <email>mckoin@uw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Charles Landis, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 31, 2016</lastchanged_date>
  <firstreceived_date>May 17, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
